The recent announcement that China approved Novo Nordisk's Wegovy is huge. Here's why: In a national survey conducted during 2015-2019 by China’s National Health Commission, more than half of the adult...
This year, the financial landscape has been shaped by high interest rates and tenacious inflation, a combination of scenarios that have significantly influenced various sectors of the economy. For investors,...
Plowing $9 billion into a manufacturing facility could help a successful tirzepatide launch reach new heights.
All three of these high-flying stocks could have more room to run.
A recent FDA announcement may have just put one company in the lead.
Eli Lilly and Novo Nordisk dominate the diabetes market thanks to blockbuster medications Mounjaro, Ozempic, and Rybelsus.
Despite concerns over its ability to meet surging semaglutide demand, this Danish pharmaceutical giant holds a dominant position in the diabetes and insulin markets - and now commands the lead in Europe's...
Even more revenue is on the way from additional sales of Wegovy.
Novo Nordisk just made a unique acquisition to help bolster the supply of Wegovy and Ozempic.